Disease Archives - Phonesnews.com

October 4, 2025

AI maps how a new antibiotic targets gut bacteria

For patients with inflammatory bowel disease, antibiotics can be a double-edged sword. The broad-spectrum drugs often prescribed for gut flare-ups can kill helpful microbes alongside harmful ones, sometimes worsening symptoms over time. When fighting gut inflammation, you don’t always want to bring a sledgehammer to a knife fight.

Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and McMaster University have identified a new compound that takes a more targeted approach. The molecule, called enterololin, suppresses a group of bacteria linked to Crohn’s disease flare-ups while leaving the rest of the microbiome largely intact. Using a generative AI model, the team mapped how the compound works, a process that usually takes years but was accelerated here to just months.

“This discovery speaks to a central challenge in antibiotic development,” says Jon Stokes, senior author of a new paper on the work,

» Read More

September 18, 2025

Inflammation jolts “sleeping” cancer cells awake, enabling them to multiply again

Cancer cells have one relentless goal: to grow and divide. While most stick together within the original tumor, some rogue cells break away to traverse to distant organs. There, they can lie dormant — undetectable and not dividing — for years, like landmines waiting to go off.

This migration of cancer cells, called metastasis, is especially common in breast cancer. For many patients, the disease can return months — or even decades — after initial treatment, this time in an entirely different organ.

Robert Weinberg, the Daniel K. Ludwig Professor for Cancer Research at MIT and a Whitehead Institute for Biomedical Research founding member, has spent decades unraveling the complex biology of metastasis and pursuing research that could improve survival rates among patients with metastatic breast cancer — or prevent metastasis altogether.

In his latest study, Weinberg, postdoc Jingwei Zhang, and colleagues ask a critical question: What causes these dormant cancer cells to erupt into a frenzy of growth and division?

» Read More

September 12, 2025

New RNA tool to advance cancer and infectious disease research and treatment

Researchers at the Antimicrobial Resistance (AMR) interdisciplinary research group of the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have developed a powerful tool capable of scanning thousands of biological samples to detect transfer ribonucleic acid (tRNA) modifications — tiny chemical changes to RNA molecules that help control how cells grow, adapt to stress, and respond to diseases such as cancer and antibiotic‑resistant infections. This tool opens up new possibilities for science, health care, and industry — from accelerating disease research and enabling more precise diagnostics to guiding the development of more effective medical treatments for diseases such as cancer and antibiotic-resistant infections.

For this study, the SMART AMR team worked in collaboration with researchers at MIT, Nanyang Technological University in Singapore, the University of Florida, the University at Albany in New York, and Lodz University of Technology in Poland.

» Read More

September 11, 2025

Technology originating at MIT leads to approved bladder cancer treatment

At MIT, a few scribbles on a whiteboard can turn into a potentially transformational cancer treatment.

This scenario came to fruition this week when the U.S. Food and Drug Administration approved a system for treating an aggressive form of bladder cancer. More than a decade ago, the system started as an idea in the lab of MIT Professor Michael Cima at the Koch Institute for Integrative Cancer Research, enabled by funding from the National Institutes of Health and MIT’s Deshpande Center.

The work that started with a few researchers at MIT turned into a startup, TARIS Biomedical LLC, that was co-founded by Cima and David H. Koch Institute Professor Robert Langer, and acquired by Johnson & Johnson in 2019. In developing the core concept of a device for local drug delivery to the bladder — which represents a new paradigm in bladder cancer treatment — the MIT team approached drug delivery like an engineering problem.

» Read More

August 31, 2025

Locally produced proteins help mitochondria function

Our cells produce a variety of proteins, each with a specific role that, in many cases, means that they need to be in a particular part of the cell where that role is needed. One of the ways that cells ensure certain proteins end up in the right location at the right time is through localized translation, a process that ensures that proteins are made — or translated — close to where they will be needed. MIT professor of biology and Whitehead Institute for Biomedical Research member Jonathan Weissman and colleagues have studied localized translation in order to understand how it affects cell functions and allows cells to quickly respond to changing conditions.

Now, Weissman, who is also a Howard Hughes Medical Institute Investigator, and postdoc in his lab Jingchuan Luo have expanded our knowledge of localized translation at mitochondria, structures that generate energy for the cell. In an open-access paper published today in Cell,

» Read More

August 29, 2025

MIT researchers develop AI tool to improve flu vaccine strain selection

Every year, global health experts are faced with a high-stakes decision: Which influenza strains should go into the next seasonal vaccine? The choice must be made months in advance, long before flu season even begins, and it can often feel like a race against the clock. If the selected strains match those that circulate, the vaccine will likely be highly effective. But if the prediction is off, protection can drop significantly, leading to (potentially preventable) illness and strain on health care systems.

This challenge became even more familiar to scientists in the years during the Covid-19 pandemic. Think back to the time (and time and time again), when new variants emerged just as vaccines were being rolled out. Influenza behaves like a similar, rowdy cousin, mutating constantly and unpredictably. That makes it hard to stay ahead, and therefore harder to design vaccines that remain protective.

To reduce this uncertainty,

» Read More

August 17, 2025

Using generative AI, researchers design compounds that can kill drug-resistant bacteria

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA).

Using generative AI algorithms, the research team designed more than 36 million possible compounds and computationally screened them for antimicrobial properties. The top candidates they discovered are structurally distinct from any existing antibiotics, and they appear to work by novel mechanisms that disrupt bacterial cell membranes.

This approach allowed the researchers to generate and evaluate theoretical compounds that have never been seen before — a strategy that they now hope to apply to identify and design compounds with activity against other species of bacteria.

“We’re excited about the new possibilities that this project opens up for antibiotics development. Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering.

» Read More

August 9, 2025

Scientists apply optical pooled CRISPR screening to identify potential new Ebola drug targets

The following press release was issued today by the Broad Institute of MIT and Harvard.

Although outbreaks of Ebola virus are rare, the disease is severe and often fatal, with few treatment options. Rather than targeting the virus itself, one promising therapeutic approach would be to interrupt proteins in the human host cell that the virus relies upon. However, finding those regulators of viral infection using existing methods has been difficult and is especially challenging for the most dangerous viruses like Ebola that require stringent high-containment biosafety protocols.

Now, researchers at the Broad Institute and the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University have used an image-based screening method developed at the Broad to identify human genes that, when silenced, impair the Ebola virus’s ability to infect. The method, known as optical pooled screening (OPS), enabled the scientists to test, in about 40 million CRISPR-perturbed human cells,

» Read More

July 18, 2025

MIT launches a “moonshot for menstruation science”

The MIT Health and Life Sciences Collaborative (MIT HEALS) has announced the establishment of the Fairbairn Menstruation Science Fund, supporting a bold, high-impact initiative designed to revolutionize women’s health research.

Established through a gift from Emily and Malcolm Fairbairn, the fund will advance groundbreaking research on the function of the human uterus and its impact on sex-based differences in human immunology that contribute to gynecological disorders such as endometriosis, as well as other chronic systemic inflammatory diseases that disproportionately affect women, such as Lyme disease and lupus. The Fairbairns, based in the San Francisco Bay Area, have committed $10 million, with a call to action for an additional $10 million in matching funds.

“I’m deeply grateful to Emily and Malcolm Fairbairn for their visionary support of menstruation science at MIT. For too long, this area of research has lacked broad scientific investment and visibility, despite its profound impact on the health and lives of over half the population,” says Anantha P.

» Read More

July 16, 2025

How to more efficiently study complex treatment interactions

MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their approach allows scientists to efficiently estimate how combinations of treatments will affect a group of units, such as cells, enabling a researcher to perform fewer costly experiments while gathering more accurate data.

As an example, to study how interconnected genes affect cancer cell growth, a biologist might need to use a combination of treatments to target multiple genes at once. But because there could be billions of potential combinations for each round of the experiment, choosing a subset of combinations to test might bias the data their experiment generates.

In contrast, the new framework considers the scenario where the user can efficiently design an unbiased experiment by assigning all treatments in parallel, and can control the outcome by adjusting the rate of each treatment.

The MIT researchers theoretically proved a near-optimal strategy in this framework and performed a series of simulations to test it in a multiround experiment.

» Read More